New eyedrop shows promise for Mite-Related dry eye

NCT ID NCT05454956

Completed Disease control Sponsor: Tarsus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an eyedrop called TP-03 in 39 people with meibomian gland dysfunction (a common cause of dry eye) linked to Demodex mites. The goal was to compare two dosing schedules (twice vs. three times daily) for safety and effectiveness. The results could lead to a new treatment for this uncomfortable condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TP-03 (lotilaner ophthalmic solution 0.25%)
What this could lead to: If successful, this could lead to a new eyedrop treatment for dry eye and eyelid inflammation caused by Demodex mites.
What could go wrong: This is a small, early Phase 2 pilot study with only 39 participants. The results may not apply to everyone, and the treatment may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEPHARITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blepharitis Demodex folliculitis demodicidosis Meibomian Gland Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEPHARITIS DEMODEX INFESTATION MEIBOMIAN GLAND DYSFUNCTION

Contacts and locations

Locations

CORE Inc.

Shelby, North Carolina, 28150, United States
Medical Optometry America

New Freedom, Pennsylvania, 17349, United States
Mitchell C. Shultz, MD

Northridge, California, 91325, United States
Oculus Research

Cary, North Carolina, 27513, United States
Silverstein Eye Center

Kansas City, Missouri, 64133, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.